Effect of nutritional intervention on intestinal barrier in patients with end-stage liver disease

doi:10.3969/j.issn.1006-7795.2018.05.026

Abstract

Abstract: The intestine plays an important barrier function, apart from the functions of digestion, absorption and secretion. Most patients with end-stage liver disease have impaired functions of intestinal barrier, leading to bacterial translocation and endotoxemia, which further aggravates liver injury. Malnutrition is also a common complication of patients with end-stage liver disease. The nutritional status of patients directly affects the occurrence, development and prognosis of liver disease. Maintaining the function of the intestinal barrier through nutritional intervention has important clinical significance for the treatment of end-stage liver disease. This review is intended to summarize the latest progresses in this area.

Key words: end-stage liver disease, nutrition, intestinal barrier

CLC Number:

R575

Bi Yanzhen, Chen Yu. Effect of nutritional intervention on intestinal barrier in patients with end-stage liver disease[J]. Journal of Capital Medical University, 2018, 39(5): 759-764.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.05.026

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I5/759

References

[1] Schmid-Schönbein G W, Chang M. The autodigestion hypothesis for shock and multi-organ failure[J]. Ann Biomed Eng, 2014, 42(2):405-414.
[2] Giannelli V, Di Gregorio V, Iebba V, et al. Microbiota and the gut-liver axis:bacterial translocation, inflammation and infection in cirrhosis[J]. World J Gastroenterol, 2014, 20(45):16795-16810.
[3] Maharshi S, Sharma B C, Srivastava S. Malnutrition in cirrhosis increases morbidity and mortality[J]. J Gastroenterol Hepatol, 2015, 30(10):1507-1513.
[4] Beaufrère A M, Neveux N, Patureau Mirand P, et al. Long-term intermittent glutamine supplementation repairs intestinal damage (structure and functional mass) with advanced age:assessment with plasma citrulline in a rodent model[J]. J NutrHealth Aging, 2014, 18(9):814-819.
[5] Reiberger T, Ferlitsch A, Payer B A, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J]. J Hepatol, 2013, 58(5):911-921.
[6] Turner J R. Intestinal mucosal barrier function in health and disease[J]. Nat Rev, 2009, 9(11):799-809.
[7] Woodhouse C A, Patel V C, Singanayagam A, et al. Review article:the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J]. Aliment Pharmacol Ther, 2018, 47(2):192-202.
[8] Traykova D, Schneider B, Chojkier M, et al. Blood microbiome quantity and the hyperdynamic circulation in decompensated cirrhotic patients[J]. PLoS One, 2017, 12(2):e0169310.
[9] Assimakopoulos S F, Tsamandas A C, Tsiaoussis G I, et al. Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis[J]. Ann Hepatol, 2013, 12(2):301-317.
[10] Assimakopoulos S F, Tsamandas A C, Tsiaoussis G I, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis:a pathogenetic mechanism of intestinal hyperpermeability[J].Eur J Clin Invest, 2012, 42(4):439-446.
[11] Ye D, Guo S, Al-Sadi R, et al. MicroRNA regulation of intestinal epithelial tight junction permeability[J]. Gastroenterology, 2011, 141(4):1323-1333.
[12] Assimakopoulos S F,Charonis A S. Uncovering the molecular events associated with increased intestinal permeability in liver cirrhosis:the pivotal role of enterocyte tight junctions and future perspectives[J]. J Hepatol, 2013, 59(5):1144-1146.
[13] Schierwagen R, Alvarez-Silva C, Madsen M S A, et al. Circulating microbiome in blood of different circulatory compartments[J]. Gut, 2018, pii:gutjnl-2018-316227.
[14] Elamin E E, Masclee A A, Dekker J, et al. Ethanol metabolism and its effects on the intestinal epithelial barrier[J]. Nutr Rev, 2013, 71(7):483-499.
[15] Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction:distinctive features and clinical relevance[J].J Hepatol, 2014, 61(6):1385-1396.
[16] Muñoz L, Albillos A, Nieto M, et al.Mesenteric Th1 polarization and monocyte TNF-alpha production:first steps to systemic inflammation in rats with cirrhosis[J]. Hepatology, 2005, 42(2):411-419.
[17] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513(7516):59-64.
[18] Ponziani F R, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J].Hepatology, 2018. doi:10.1002/hep.30036.
[19] Limin S, Masayuki F, Nanthakumar T, et al. Toll -like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria[J]. Gastroenterology, 2008, 135(2):529-538.
[20] Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segamented filamentous bacteria in IgA-deficient gut[J]. Proc Natl Acad Sci USA, 2004, 101(7):1981-1986.
[21] Tang Q J, Wang L M, Tao K Z, et al. Expression of polymeric immunoglobulin receptor mRNA and protein in human paneth cells:paneth cells participate in acquired immunity[J]. Am J Gastroenterol, 2006, 101(7):1625-1632.
[22] Chen Y, Guo J, Qian G, et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality[J]. J Gastroenterol Hepatol, 2015, 30(9):1429-1437.
[23] Mehta A K, Lyon G M 3rd. Infectious diseases in end-stage liver disease patients[J]. Crit Care Nurs Clin North Am, 2010, 22(3):291-307.
[24] Yu L, Yan H, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J]. Hepatology, 2010, 52(4):1322-1333.
[25] Zhang H, Yu L, Yang W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J]. J Hepatol, 2012, 57(4):803-812.
[26] Dapito D H, Mencin A, Gwak G Y, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J]. Cancer Cell, 2012, 21(4):504-516.
[27] Tao X, Wang N, Qin W. Gut microbiota and hepatocellular carcinoma[J]. Gastrointest Tumors, 2015, 2(1):33-40.
[28] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for earlyhepatocellular carcinoma[J]. Gut, 2018, pii:gutjnl-2017-315084.
[29] Sanduzzi Z M, Rocco A, Compare D, et al. The gut microbiota:a new potentiall driving force in liver cirrhosis and hepatocellular carcinoma[J]. United European Gastroenterol J, 2017, 5(7):944-953.
[30] Aguirre Valadez J M, Rivera-Espinosa L, Méndez-Guerrero O, et al. Intestinal permeability in a patient with liver cirrhosis[J]. Ther Clin Risk Manag, 2016, 12:1729-1748.
[31] Adams D H, Eksteen B, Curbishley S M. Immunology of the gut andliver:a love/hate relationship[J]. Gut, 2008, 57(6):838-848.
[32] Dodd D, Spitzer M H, Van T W, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites[J]. Nature, 2017, 551(7682):648-652.
[33] Seidel D V, Azcárate-Peril M A, Chapkin R S, et al. Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk[J]. Semin Cancer Biol, 2017, 46:191-204.
[34] Lyu M, Wang Y F, Fan G W, et al. Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota[J]. Front Microbiol, 2017, 8:2146.
[35] Desai M S, Seekatz A M, Koropatkin N M, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibiliy[J]. Cell, 2016, 167(5):1339-1353.e21.
[36] Sonnenburg E D, Smits S A, Tikhonov M, et al. Diet-induced extinctions in the gut microbiota compound over generations[J]. Nature, 2016, 529(7585):212-215.
[37] Parker E A, Roy T, D'Adamo C R, et al. Probiotics and gastrointestinal conditions:An overview of evidence from the cochrane collaboration[J]. Nutrition, 2018, 45:125-134.e11.
[38] Merli M, Iebba V, Giusto M. What is new about diet in hepatic encephalopathy[J]. Metab Brain Dis, 2016, 31(6):1289-1294.
[39] Marlicz W, Wunsch E, Mydlowska M, et al. The effect of short term treatment withprobiotic VSL#3 on various clinical and biochemical parameters in patients with livercirrhosis[J]. J Physiol Pharmacol, 2016, 67(6):867-877.
[40] Zhernakova A, Kurilshikov A, Bonder M J, et al.Population-based metage omics analysis reveals markers for gut microbiome composition and diversit[J]. Science, 2016, 352(6285):565-569.
[41] Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation[J]. Science,2016, 352(6285):560-564.
[42] Leitão-Gonçalves R, Carvalho-Santos Z, Francisco A P,et al. Commensal bacteria and essential amino acids control food choice behavior and reproduction[J]. PLoS Biol, 2017, 15(4):e2000862.
[43] Singh R K, Chang H W, Yan D, et al. Influence of diet on the gut microbiome and implications for human health[J]. J Transl Med, 2017, 15(1):73.